Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 9/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.37 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29622914 | 0.96 | SLC15A2 (0.38) | SLC15A2FURIN | |
| SCHEMBL29530561 | 0.95 | SLC15A2 (0.39) | SLC15A2 | |
| SCHEMBL29381521 | 0.94 | BACE1 (0.40) | SLC15A2BACE1BACE2CTSD | |
| SCHEMBL29833166 | 0.94 | CALCR (0.38) | SLC15A2 | |
| SCHEMBL31514341 | 0.93 | BACE1 (0.38) | SLC15A2BACE1BACE2CTSD | |
| SCHEMBL4216003 | 0.93 | CALCR (0.39) | BACE1BACE2CTSD | |
| SCHEMBL29732685 | 0.91 | SLC15A2 (0.44) | SLC15A2FURIN | |
| SCHEMBL30296849 | 0.91 | SLC15A2 (0.38) | SLC15A2FURIN | |
| SCHEMBL30008256 | 0.91 | BACE1 (0.39) | BACE1BACE2CTSD | |
| SCHEMBL30441425 | 0.90 | SLC15A2 (0.43) | SLC15A2BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388650-A1 | OLIGO-TRAP FUSION PROTEINS (OFPs) AND USES THEREOF | ENOSI THERAPEUTICS CORP (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024186690-A2 | OLIGO-TRAP FUSION PROTEINS (OFPS) AND USES THEREOF | ENOSI THERAPEUTICS CORPORATION (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2023168426-A1 | COMPOSITIONS AND CELLS CONTAINING MIXTURES OF OLIGO-TRAP FUSION PROTEINS (OFPS) AND USES THEREOF | ENOSI THERAPEUTICS CORPORATION (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388650-A1 | OLIGO-TRAP FUSION PROTEINS (OFPs) AND USES THEREOF | TNFSF11, TNFRSF9, FCER2 | SLC15A2 4163/4885BACE1 3817/4885BACE2 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.